The company's independent production and research and development capabilities are strong, anti-cancer new drugs will become a profit growth point, the current bottom is gradually rising, pay attention to waiting for opportunities is better, is expected to have a large room for growth in the future.
![17 billion! Crus's family is amazing: Shuanghe, Sanjiu, Jiangzhong, Dong'a...[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)
36Kr was informed that CR Shuanghe announced that the board of directors agreed that the company through the innovation division from Novita Pharmaceuticals, Inc. (NOVI...
11-11
Editor's note: Can the pharmaceutical and biological industry usher in the long-awaited golden age of scientific research and application? What kind of actions and observations do industry researchers, important company practitioners, investors and observers have...
11-11
E company news, on November 11, China Resources Shuanghe class of anti-cancer drugs landed and Haikou National High-tech Zone and China Resources Shuanghe signing ceremony was held in Haikou City. The two sides signed the "Haikou National High...
11-13
Every TIME after the AI news, some investors asked questions on the investor interaction platform: Does the company supply CR Shuanghe antiviral APIs, and which ones are specific? Thank you Tuoxin Pharmaceutical (301089...
11-23
【Caihua News】This morning, as of 10:00, the heparin concept plate fell. China Resources Shuanghe (600062.CN) fell 2.87% to 12.53 yuan, Dongcheng Medicine...
11-30
